Ken Janoski
About Ken Janoski
Ken Janoski serves as the Senior Director of Investments at the North Carolina Biotechnology Center, a position he has held since 2018. He has extensive experience in the biotechnology sector, having previously worked as President & CEO of BioGenerator and held a director role at Andersen Consulting.
Current Role at North Carolina Biotechnology Center
Ken Janoski serves as the Senior Director of Investments at the North Carolina Biotechnology Center. He has held this position since 2018, contributing to the organization's mission of advancing biotechnology in North Carolina. His role involves overseeing investment strategies and providing financial support to emerging biotech companies, fostering innovation and growth within the sector.
Previous Experience at Andersen Consulting
Prior to his current role, Ken Janoski worked at Andersen Consulting, now known as Accenture, as a Director from 1994 to 1999. During his five-year tenure, he gained extensive experience in consulting, focusing on strategic financial management and investment strategies.
Leadership at BioGenerator
Ken Janoski was the President and CEO of BioGenerator from 2006 to 2009. In this leadership role, he was responsible for driving the organization's efforts to support early-stage biotech companies through financial investments and strategic guidance.
Educational Background in Finance
Ken Janoski holds a Master of Business Administration (M.B.A.) from Washington University in St. Louis, where he studied Finance. He also earned a Bachelor of Science in Business Administration from the University of Missouri-Saint Louis. Additionally, he completed Venture Capital University at the University of California, Berkeley - School of Law, enhancing his expertise in venture capital and investment strategies.
Investment Contributions to Biotech Companies
Throughout his career, Ken Janoski has played a significant role in providing early-stage financial support to various biotech companies. His contributions include supporting Higgs Boson Health, Lindy Biosciences, Emergo Therapeutics, Dualogics, Cereius, Arrevus, Locus Biosciences, Tellus Therapeutics, RainBIO, NabGen, KindHeart, and Advanced Chemotherapy Technologies, among others.